Analysis of the Clinicopathological Characteristics, Genetic Phenotypes, and Prognostic of Pure Mucinous Adenocarcinoma

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Nov 27

PMID 31769218

Citations 9

Authors

Zhencong Chen

Ming Li

Ke Ma

Guoguo Shang

Jiaqi Liang

Jiacheng Yin

Jizhuang Luo

Cheng Zhan

Yu Shi

Qun Wang

Affiliations

Soon will be listed here.

Abstract

Background: Primary pure mucinous adenocarcinoma of the lung (PMA) is a rare subtype. However, correlations between clinicopathological features and genetic phenotypes with survival have not been described comprehensively.

Methods: Pure mucinous adenocarcinoma patient information collected from the Surveillance, Epidemiology, and End Results (SEER) database, the Department of Thoracic Surgery, Zhongshan Hospital, Fudan University (FDZSH), and the Cancer Genome Atlas (TCGA) were extracted, evaluated, and compared with other lung adenocarcinomas (LUAD) patient data. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses were performed to explore the functional importance of underlying molecular changes. Overall survival (OS) was evaluated with the Kaplan-Meier method. Univariate and multivariate analysis through Cox proportional hazard regression identified risk factors that predicted OS, and the results were used to construct a nomogram to predict OS for PMA patients.

Results: Overall, 3622 patients, 41 patients, and 15 patients with PMA were identified from the SEER, FDZSH, and TCGA databases, respectively. There were 345 differentially expressed genes, 30 differentially mutated genes and 72 differentially methylated genes were identified between PMA and other LUAD samples. In the SEER database, PMA had a better prognosis compared to other LUAD. Compared with patients with other LUAD, patients with PMA exhibited unique clinicopathological features, including fewer grade III/IV tumors, less pleural invasion, more early-stage cancer, and more lower lobe carcinomas. Multivariate analyses showed that age, race, T stage, N stage, surgery, and chemotherapy were independent risk factors. The nomogram had a calibration index of 0.724.

Conclusions: Our research identified unique clinicopathological characteristics and genetic phenotypes for PMA and other LUAD. The nomogram accurately predicted OS.

Citing Articles

Sublobectomy versus lobectomy for peripheral small-sized pulmonary mucinous adenocarcinoma.

Yang Z, Yang F, Li Z, Fernando H, Li X, Jiang G J Thorac Dis. 2025; 17(1):390-399.

PMID: 39975724 PMC: 11833556. DOI: 10.21037/jtd-2024-2096.

Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma.

Ge Q, Zheng C, Zhang G, Cong Z, Luo J, Xu Y BMC Cancer. 2024; 24(1):925.

PMID: 39085796 PMC: 11289994. DOI: 10.1186/s12885-024-12714-8.

[Construction of a Prognostic Prediction Model of Patients with Pathologic N0  in Resected Invasive Mucinous Adenocarcinoma of the Lung].

Wang Z, He J, Shen H, Chen X, Lin C, Yu H Zhongguo Fei Ai Za Zhi. 2024; 27(1):47-55.

PMID: 38296625 PMC: 10895294. DOI: 10.3779/j.issn.1009-3419.2024.106.02.

Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.

Xu M, Hao Y, Zhou H, Shi Z, Si J, Song Z Med Oncol. 2023; 40(7):198.

PMID: 37294384 DOI: 10.1007/s12032-023-02059-w.

Comparison of treatment strategies for resectable locally advanced primary mucinous adenocarcinoma of the lung.

Gu Y, Zhu H, Deng J, Zhang J, Chen T, Lai S Cancer Med. 2023; 12(8):9303-9312.

PMID: 36789657 PMC: 10166977. DOI: 10.1002/cam4.5684.

References

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F . Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2012; 8(1):52-61. DOI: 10.1097/JTO.0b013e3182769aa8. View

Sun F, Ma K, Yang X, Li M, Shi Y, Zhan C . A nomogram to predict prognosis after surgery in early stage non-small cell lung cancer in elderly patients. Int J Surg. 2017; 42:11-16. DOI: 10.1016/j.ijsu.2017.04.024. View

Hwang D, Sholl L, Rojas-Rudilla V, Hall D, Shivdasani P, Garcia E . KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2016; 11(4):496-503. DOI: 10.1016/j.jtho.2016.01.010. View

Yanagawa N, Shiono S, Abiko M, Ogata S, Sato T, Tamura G . New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol. 2013; 8(5):612-8. DOI: 10.1097/JTO.0b013e318287c3eb. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L . The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Tumour Biol. 2015; 36(8):6417-24. DOI: 10.1007/s13277-015-3331-4. View

Dacic S . Pros: the present classification of mucinous adenocarcinomas of the lung. Transl Lung Cancer Res. 2017; 6(2):230-233. PMC: 5420543. DOI: 10.21037/tlcr.2017.04.11. View

Zhao M, Zhan C, Li M, Yang X, Yang X, Zhang Y . Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma. J Thorac Dis. 2018; 10(1):398-407. PMC: 5863124. DOI: 10.21037/jtd.2017.12.68. View

Luo J, Ma K, Shi Y, Chen Z, Zhao M, Huang Y . Genetic analyses of differences between solid and nonsolid predominant lung adenocarcinomas. Thorac Cancer. 2018; 9(12):1656-1663. PMC: 6275839. DOI: 10.1111/1759-7714.12876. View

10.

Schuettengruber B, Bourbon H, Di Croce L, Cavalli G . Genome Regulation by Polycomb and Trithorax: 70 Years and Counting. Cell. 2017; 171(1):34-57. DOI: 10.1016/j.cell.2017.08.002. View

11.

Li H, Jiang C, Wu D, Shi S, Liao M, Wang J . The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis. PLoS One. 2017; 12(7):e0180271. PMC: 5507401. DOI: 10.1371/journal.pone.0180271. View

12.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Lee H, Cha M, Lee K, Lee H, Kwon O, Choi J . Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas. J Thorac Oncol. 2016; 11(7):1064-73. DOI: 10.1016/j.jtho.2016.03.011. View

15.

Marabese M, Ganzinelli M, Garassino M, Shepherd F, Piva S, Caiola E . KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015; 6(32):34014-22. PMC: 4741822. DOI: 10.18632/oncotarget.5607. View

16.

Kadota K, Yeh Y, DAngelo S, Moreira A, Kuk D, Sima C . Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014; 38(8):1118-27. PMC: 4666292. DOI: 10.1097/PAS.0000000000000246. View

17.

Chen Z, Li M, Ma K, Shang G, Liang J, Yin J . Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. Cancer Med. 2019; 9(2):517-529. PMC: 6970056. DOI: 10.1002/cam4.2726. View

18.

Wang H, Schabath M, Liu Y, Berglund A, Bloom G, Kim J . Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival. Clin Lung Cancer. 2015; 16(6):e141-63. PMC: 4609593. DOI: 10.1016/j.cllc.2015.05.007. View

19.

Yang X, Sun F, Chen L, Shi M, Shi Y, Lin Z . Prognostic value of visceral pleural invasion in non-small cell lung cancer: A propensity score matching study based on the SEER registry. J Surg Oncol. 2017; 116(3):398-406. DOI: 10.1002/jso.24677. View

20.

Sun F, Wang P, Zheng Y, Jia W, Liu F, Xiao W . Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. Oncol Lett. 2018; 15(1):489-494. PMC: 5766062. DOI: 10.3892/ol.2017.7312. View